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1. Introduction  
Although HIV-positive individuals kept a central role in the maintenance of the epidemic, 
only from the 12th World AIDS Conference, held in Geneva in 1998, the sexuality of people 
living with HIV/AIDS received more systematic attention (Schiltz and Sandfort 2000). After 
receiving the diagnosis of HIV infection is common for people to become involved in a state 
of negative mood and decrease the frequency of sexual activity and those who remain with 
sexual practices most likely do so without adequate protection (Rosser, Gobby and Carr 
1999). The adhesion to safe sex practices after diagnosis of HIV infection may have a 
negative impact on sexual functioning of most subjects (Newshan, Taylor and Gold 1998). 
The individuals that have partnership are significantly more likely to maintain sexual 
activity than those without (Stein et al. 2005). On the professionals, the sexual functioning is 
often overlooked among the care of HIV positive patients. Generally, information about the 
relationship between hormonal factors, psychological factors, drug effects, disease stage, 
and sexual functioning are not spoken by health professionals (Newshan et al. 1998). In 
addition, one must consider that individuals who acquire HIV through sexual or parenteral 
(excluding blood transfusions) are already part of a population at higher risk for sexual 
dysfunction, as many risk factors for HIV are also to the occurrence of sexual dysfunction, 
such as conflicts with the orientation or sexual identity, depression, and psychological 
problems related to self-image (Hijazi, Nandwani and Kell 2002). 
Several factors may modify the sexual response. Beginning in youth, sexual dysfunctions are 
highly prevalent in all age groups. Symptoms of sexual dysfunction include erectile 
dysfunction, loss of libido, premature or delayed ejaculation, orgasmic disturbances, arousal 
difficulties, and dyspareunia, among others (Lewis et al. 2004).  
For the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) ((APA) 2000), the fundamental concepts of the principals sexual dysfunctions 
are: Dyspareunia is recurrent or persistent genital pain associated with sexual intercourse in 
men or women. Female orgasmic disorder is the delay of orgasm following normal excitement 
and sexual activity. Due to the widely varied sexual response in women, it must be judged 
by a clinician to be significant taking into account the person’s age and situation. Female 
sexual arousal disorder is inability to attain or maintain until completion of sexual activity 
adequate lubrication in response to sexual excitement. Hypoactive sexual desire disorder is 
deficient or absent sexual fantasies and desire for sexual activity. This judgment must be 
made by a clinician taking into account the individual’s age and life circumstances. Male 
erectile disorder (impotence) is recurring inability to achieve or maintain an erection until 
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completion of the sexual activity. Male orgasmic disorder is delay or absence of orgasm 
following normal excitement and sexual activity. Due to the widely varied sexual response 
in men, it must be judged by a clinician to be significant, taking into account the person’s 
age and situation. Premature ejaculation is the ejaculation with minimal sexual stimulation 
before or shortly after penetration and before the person wishes it. The condition is 
persistent or occurs frequently and causes significant distress (APA, 2000). 
Factors such as lack of ability, poor sex education, and psychological conflicts play an 
important role in the development of sexual dysfunction at the start of sexual activity (Lewis 
et al. 2004). Life habits and morbid conditions become important risk factors for sexual 
dysfunction during aging; these factors include hypertension, diabetes, depression, heart 
disease, sex hormone deficiency, smoking, sedentary life style, and drug addiction (Moreira 
et al. 2001).  Socioeconomic factors, such as education, employment and marital status, have 
also been related to sexual difficulties (Nicolosi et al. 2003).  
Highly active antiretroviral therapy (HAART) has previously been shown to provide the 
best clinical management for HIV-infected patients, as it decreases the prevalence of 
hypogonadism and advanced HIV disease, which are principal causes of sexual dysfunction 
in people infected with HIV (Danoff 1996, Collazos 2007). However the prevalence on sexual 
dysfunctions in the HAART years show high rates (Collazos 2007). In this chapter we 
analyze the etiologic factors involved on sexual dysfunctions of HIV/AIDS people. We also 
describe the most prevalent sexual dysfunctions in males, and females. We propose steps for 
assessment, and diagnosis of the sexual dysfunction in HIV/AIDS people. We talk about the 
principal therapeutic strategies for recover healthy sexual function of this people. Finally, 
we comment on the prognostic factors.   
2. Epidemiology 
The prevalence rates of sexual dysfunctions in HIV/AIDS patients were reviewed: 46% 
presented with erectile dysfunction  (range 9-74%), 39% with ejaculatory disturbances 
(range 36-42%), 44% with decreased libido  (range 24-73%), and 27% with orgasmic 
disorders (range 7-49%). The high interval of range is because so much different designs and 
methods used in the HIV sexual dysfunctions studies (Collazos 2007).  There are differences 
on the most prevalent sexual dysfunctions among men, and women.  
The most prevalent female sexual dysfunctions are low sexual desire, orgasmic dysfunction, 
and dyspareunia (Hijazi et al. 2002, Luzi et al. 2009). A higher frequency (36%) of sexual 
inactivity during the last 12 months in female with AIDS has been reported by a Brazilian 
study (de Tubino Scanavino and Abdo 2010), which is in according with another study of 
females with HIV/AIDS, of which 28% reported having no sexual partners for an average of 
69 months (Lambert, Keegan and Petrak 2005). We already know that HIV/AIDS females 
that has partners keep more the sexual activity than who does not have. But in the Brazilian 
study the female also does not maintain sexual arousal until the end of the sex, and probably 
this may partly explain the sexual inactivity because these women seem to find sex 
unsatisfactory (de Tubino Scanavino and Abdo 2010).  
On men infected by HIV the most prevalent sexual dysfunctions are erectile dysfunction 
and premature ejaculation. In Brazil, a case-control study nested in a cross-sectional 
population study with people who reported AIDS found that  almost 50% of the male 
reported ejaculatory symptoms, and 33% of the men living with AIDS reported erectile 
dysfunction (de Tubino Scanavino and Abdo 2010). In this study 12% of men with AIDS also 
www.intechopen.com
 Sexual Dysfunctions   
 
505 
reported dyspareunia, while no men without AIDS reported it (de Tubino Scanavino and 
Abdo 2010). Male dyspareunia is not commonly reported in the literature, possibly because 
it is not regularly investigated in studies of male sexual function.  
3. Etiology 
There are four important factors associated with sexual dysfunctions in HIV/AIDS patients: 
mental, hormonal, pharmachological, and other morbid conditions.  
3.1 Mental factors 
At the first moment, the condition of being HIV seropositive may cause feelings of loss of 
sexual attractiveness, reduction of sexual desire and sexual satisfaction. Moreover, they may 
be confronted with the absence of sexual partners, particularly when revealing their 
serological status. In addition, the sexual response may be undermined by fear or guilt in 
coming to contaminate partnerships (Newshan et al. 1998, Schiltz and Sandfort 2000).  
A representative French study with HIV outpatients showed association among sexual 
difficulties and the discrimination by friends and partners, suffering by lipodystrophy, very 
disturbing HIV related symptoms. The authors recommend psychological support for HIV 
experience for improves the sexual life (Bouhnik et al. 2008). Feelings of guilt by have 
acquiring the HIV on sexual transmission may become a psychogenic factor and influence 
negatively the sexual response. Maybe because of this point, sexual dysfunctions are more 
prevalent on homosexual men than intravenous drug users (Sollima et al. 2001).  In fact, gay 
and bisexual men have higher rates of sexual dysfunctions (Catalan and Meadows 2000) or 
just complaint more to the physicians on the disorder due to valorize more the sexual 
function than others. 
Depression is one of the most important mental factors associated with sexual dysfunctions 
(Ciesla and Roberts 2001). A study on 300 HIV infected men found the older age and 
depression were associated with erectile dysfunction, and current higher CD4 account was 
protective (Crum-Cianflone et al. 2007).  
The most common factors associated with female sexual dysfunction are the psychosocial 
aspects of HIV infection and the negative body image associated with use of medications 
that cause lipodystrophy (Bell et al. 2006, Hijazi et al. 2002, Luzi et al. 2009). 
3.2 Hormonal factors 
Hypogonadism was one of the most frequent causes of sexual dysfunction before HAART. 
Currently,   HIV infected individuals may have testosterone levels higher than non infected 
individuals. Moreover, estradiol is often higher in men (50% of them) on HAART possibly 
because the augmentation of the peripheral conversion of the androgens to estrogens in 
lipid tissues (Bell et al. 2006, Goldmeier et al. 2002). But the role of estradiol in HIV sexual 
dysfunctions is not clear. The expected decrease in blood of the gonadotropin hormones was 
not confirmed (Collazos et al. 2002a), and one study observed improving on sexual function 
despite higher blood levels of estradiol (Collazos et al. 2002b). On the other side, an study on 
rabbits found estrogen receptors in cavernous body, and found pathophysiological changes 
in erectile function when rabbits are under continuous estrogen intake (Srilatha and 
Adaikan 2004). Another study with older men found that the balance between testosterone 
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(decreased) and oestradiol (higher) are associated with erectile dysfunction (Srilatha, 
Adaikan and Chong 2007). 
Hyperprolactinemia may be associated with sexual dysfunction as it decreases the 
gonadotropin releases and have been found in part of the HIV individuals, but one study 
does not found difference in prolactin levels between patients with and without sexual 
difficulties (Collazos et al. 2002b). 
3.3 Pharmacological factors 
HAART era shows high rates of sexual dysfunction despite the improvement of health 
conditions. Anedotical report from studies suggest association among protease inhibitors 
and sexual dysfunctions, but just a few studies found a kind of evidence on it. These studies 
have found a possible effect on testosterone receptor by protease inhibitors (Yang et al. 2005, 
Baker, Vaughn and Fanestil 1978). Other evidences to explain sexual dysfunction by an 
effect of HAART are scarce. Future studies on pharmacological issues may specify the 
etiologic role of antiretrovirals to sexual dysfunction. 
It has been reported ejaculatory dysfunction associated by use of didanosine (Hijazi et al. 
2002). The neuropathy is a possible complication by use of some antiretrovirals and may be 
a sexual dysfunction factor for some patients (Rogstad et al. 1999). 
However, HIV infected individuals use a lot of other medications that are associated with 
decrease on sexual response. Medications such as ketoconazole, fluconazole, ganciclovir, 
megestrol, methadone and cimetidine may decrease the level of testosterone and cause 
sexual dysfunction (Newshan et al. 1998, Daniell 2002). Antihypertensives, diuretics, 
hypolipemics, benzodiazepines, antidepressants, and antipsychotics are also associated with 
sexual dysfuncitons (Asboe et al. 2007, Lue 2000, Daniell 2002, Bruckert et al. 1996). 
3.4 Comorbid conditions 
Some morbid conditions are common in HIV people and some of them are often associated 
with sexual dysfunction as hepathopathy,  diabetes, hyperlipidemia, hypertension, vascular 
disease, alcohol dependence (Moreira et al. 2001). 
4. Diagnosis 
When a patient comes for receiving care on sexual function, he needs time and more 
than one meeting with the health professional, to bind and reveal your intimate life 
problems.  
But if a patient seeks medical care for other reasons but also has sexual problems, difficultly 
he will talk about spontaneously. Moreover, sexual life is poored investigated by 
practitioners, indeed in mental health settings. It also occurs on HIV/AIDS clinical context. 
In a research in the United Kingdom on HIV clinics, 60% of the physicians do not ask on 
sexual functioning of female HIV infected (Bell et al. 2006) despite the sexual difficulties are 
very prevalent on HIV women.  
For this reason, in order to investigate sexual function of HIV people, the first point to 
consider is an appropriate doctor patient relationship (Lawlor and Braunack-Mayer 2004), 
which is basic to investigate clinical and sexual symptoms of the patients. It is important an 
attitude of open minded and free of judgments by the professional. 
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The diagnosis of sexual dysfunctions follows some steps for diagnosis: consistent doctor-
patient relationship, investigation of clinical history and physical examination, investigation 
of the sexual life history, assessment on sexual response, and check the hormonal serum 
levels.  
4.1 Clinical history and physical examination 
The clinical history compreends the assessment on the immunological conditions, 
comorbidities, and medications. Severe immunological damage may indicates AIDS 
diagnosis. The poor health condition undermine physical and sexual response. Nevertheless 
the hypogonadism should be investigated. On the physical examination the gynecomaestia 
and testicular atrophy may indicates hypogonadism (Rosen et al. 2006). Hypogonadism is 
defined as low levels of testosterone (< 300 nh/dL) in early morning, with associated clinical 
manifestations, including sexual dysfunction, weight and muscle mass loss, fatigue, 
depressed mood, and anemia (Crum et al. 2005). 
We already spoke on the most frequent comorbidity and the use of some medications which 
also influence the sexual response. 
4.2 Sexual history 
The sexual history should starts investigating the concepts on sexuality of the family (father 
and mother), following to the patient’s sexual history, finishing with focus about some 
specific gender issues. 
4.2.1 Sexuality on origin family 
When sexuality is very repressed, it could undermine to live a broad experience of sex and 
love in adolescence and young adult life (Basson 2008), which are fundamental to sexual 
maturing process. The non psychological and sexual maturing and possible internal 
conflicts influence the sexual response. When somebody lives in a dysfunctional family in 
childhood and has early contact with the erotic experience (sexual abuse or permissive 
family ambience), it could be traumatic and harm the personality development, as the 
children experience feelings of being unprotected, unsafety, shame or guilt. Then, this 
person could presents sexual problems (aversion, excessive drive, sexual difficulties) later in 
your life (Noll, Trickett and Putnam 2003).  
On sexual violence suffered during childhood and adolescence many studies have reported 
serious psychological effects and sexual consequences (Gwandure 2007, Greenberg 2001, 
Whetten et al. 2006). Victims of violence often have a high frequency of the stress post-
traumatic disorder, depression, suicidal ideation and low self-esteem (Gwandure 2007) 
(Greenberg 2001, Whetten et al. 2006). This psychopathological issues are risk factors for 
HIV / AIDS in adult life, as negative moods promote sexual practices without the use of 
condoms and, therefore, exposure to virus (Gwandure 2007). Thus, research has 
documented the association between childhood sexual abuse and higher frequency of sexual 
risk behavior in adult life (Gwandure 2007, Greenberg 2001, Whetten et al. 2006, Sikkema et 
al. 2008). At the same time, in several studies of HIV-positive individuals is described 
childhood sexual abuse, which frequency varies between 24% and 76% (Whetten et al. 2006, 
Bedimo, Kissinger and Bessinger 1997, Kalichman et al. 2002, Liebschutz et al. 2000, 
Segurado et al. 2008). 
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4.2.2 Own sexual history 
The own sexual history is very important. The first sexual experiences with boys or girls, the 
first complete sexual relationship, the exercise of masturbation are all significant steps in 
sexual maturing process, which compreend gaining knowledge on your body (erogenous 
zones) and of the others. When somebody has sexual difficulties in early sexual experiences 
and are not prepared to deal with, it could promote negative attitude regarding sex, and 
new experiences will be avoided, undermining the sexual maturing (Lewis et al. 2004). A 
person with sexual inexperiece is under higher risk for sexual dysfunction (Lewis et al. 
2004), and, in turn, a person with sexual dysfunction is under higher risk for unsafe sex 
behavior (Rosen et al. 2006), even if become infected by HIV.  
4.2.3 Gender issues 
Some specific gender issues are also important to be investigated. For men, homosexual 
orientation presents a special vulnerability for sexual dysfunction, maybe because the 
process to accept the sexual orientation, the difficulties to deal with low acceptance by 
family and society, and the problems with gender identity (Coleman, Rosser and Strapko 
1992). Some studies have reported higher rates of sexual dysfunction in HIV infected men 
who have sex with men (Cove and Petrak 2004).  
For women, the mental health is a strong point to be investigated. Depression is a strong 
risk factor for sexual dysfunction (Cyranowski et al. 2004) and when treated can improve 
substancially the sexual dysfunction symptoms (Clayton et al. 2007).  
Less investigated but so important is self-image and body image. Self-image compreends 
the perception from herself of the female issue, and the erotic issue. They are steps of sexual 
developing and are determinant to woman fells secure to engage in sexual experiences in 
adult life. The prejudice on body image by lipodystrophy has been considered the most 
important factor for sexual dysfunction in HIV infected women (Luzi et al. 2009) and could 
also influence to women do not engage in sex with partners.  
Another important point on female sexual function is the presence of positive feelings for 
the partner (Basson 2008) and the sexual partner hability, as we know a lot of women just 
have positive sexual experiences when they are estimulated by a partner in an appropriate 
context, which involve affect and foreplay (Basson 2008).  
4.2.4 Difference between organic and psychogenic sexual dysfunction 
It is also relevant in sexual history to distinguish between characteristcs of organic or 
psychogenic sexual dysfunction (Table 1) (Speckens et al. 1993, Hatch, de la Peña and Fisher 
1987). The psychogenic occurs more often in younger individuals, the onset is rapid, it could 
be related with adverse life events (when it appears soon after HIV diagnosis, e.g.) or 
problematic onset sex lives, the presentation is not constant and it changes depending on the 
partners, or the situations, and could not be presented in masturbation. Moreover, the 
organic occurs more often in older men, the onset is insidious, it does not have  relation with 
life adverse events, the presentation is constant, and it also occurs in masturbation. For men, 
when the nocturnal penile erection is present it is suggestive of psychogenic etiology. 
Considering HIV infection we could think that individuals just seropositive with good 
health conditions probably presents sexual dysfunction by psychogenic etiology, and 
individuals with poor imunological conditions or AIDS diagnosis probably presents sexual 
dysfunction by organic factors.  
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Characteristics Organic Psychogenic 
Age of onset Older Younger 
Onset Insidious Quick 
Pattern Constant Variable 
Masturbation Yes No 
Adverse life events 
and/or problems on 
the onset of sex life 
No Yes 
Men: penile nocturnal 
Erection 
No Yes 
Table 1. Clinical difference between organic and psychogenic sexual dysfunction 
4.3 Assessment on sexual response 
Some standardized instruments for quick assessment of sexual response can be used, as the 
health practitioners often find it difficult to investigate the sex lives of patients. For female 
we can use The Female Sexual Function Index (FSFI) to assess female sexual function. The 
FSFI is a self-responsive questionnaire with 19 multiple choice questions divided into six 
main domains. The questionnaire evaluates phases of the sexual cycle (desire, excitement 
and orgasm), sexual satisfaction and dyspareunia in the last four weeks (Rosen et al. 2000). 
For male there is The International Index of Erectile Function (IIEF) which addresses the 
relevant domains of male sexual function (erectile function, orgasmic function, sexual 
desire, intercourse satisfaction, and overall satisfaction), is psychometrically tested, readily 
self-administered in research or clinical settings (Rosen et al. 1997).  
The Figure 1 shows generally items for investigating sexual function (de Tubino Scanavino 
and Abdo 2010). 
In general items evaluating sexual function involves the  follows (de Tubino Scanavino and 
Abdo 2010): “Did you have sexual intercourse during the last 12 months?”, “Do you need to 
be stimulated by your partner to begin sexual intercourse?”, “Is stimulation (foreplay) 
necessary for you for a long time before sexual intercourse?”, “If there is no previous 
reciprocal stimulation (foreplay), do you and your partner proceed to genital sexual 
intercourse?”, “Do you masturbate regularly?”, “Do you usually have sexual desire?”, “Do 
you feel pain during sexual intercourse?”. Items evaluating female sexual function involves 
the follows: “When you kiss and hug during sexual intercourse, do you feel sexual arousal 
and does the vagina become wet?”, “Do you maintain sexual arousal and a wet vagina until 
the end of sexual intercourse?“, “Do you reach orgasm during sexual activity (inside the 
vagina or outside on the clitoris)?”. Items evaluating male sexual function involves the 
follows: “Do you feel the pleasure of getting an erection and keeping it until the end of 
sexual intercourse?”, “Do you always manage to maintain an erection (hard penis) until the 
end of sexual intercourse?”, “Do you ejaculate (expel white liquid through the penis) 
quicker than you want?”, “Do you ejaculate (expel white liquid through the penis) later than 
you want?”, “Do you ejaculate (expel white liquid through the penis) at the desired time for 
you?”. 
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Items for men and women 
“Did you have sexual intercourse during the last 12 
months?”, “Do you need to be stimulated by your partner 
to begin sexual intercourse?”, “Is stimulation (foreplay) 
necessary for you for a long time before sexual 
intercourse?”, “If there is no previous reciprocal 
stimulation (foreplay), do you and your partner proceed 
to genital sexual intercourse?”, “Do you masturbate 
regularly?”, “Do you usually have sexual desire?”, “Do 
you feel pain during sexual intercourse?”. 
Items specifically for 
women 
“When you kiss and hug during sexual intercourse, do 
you feel sexual arousal and does the vagina become wet?”, 
“Do you maintain sexual arousal and a wet vagina until 
the end of sexual intercourse?“, “Do you reach orgasm 
during sexual activity (inside the vagina or outside on the 
clitoris)?”. 
Items specifically for men 
“Do you feel the pleasure of getting an erection and 
keeping it until the end of sexual intercourse?”, “Do you 
always manage to maintain an erection (hard penis) until 
the end of sexual intercourse?”, “Do you ejaculate (expel 
white liquid through the penis) quicker than you want?”, 
“Do you ejaculate (expel white liquid through the penis) 
later than you want?”, “Do you ejaculate (expel white 
liquid through the penis) at the desired time for you?”. 
Fig. 1. Items for assessment the sexual function (de Tubino Scanavino and Abdo 2010). 
4.4 Laboratory assessment 
Laboratory assessment may involve a sexual hormones screening including testosterone, 
estrogen, estradiol, prolactin, gonadotropin. It is important check the serum free 
testosterone or the levels of sex hormone-binding globulin because it usually is increased in 
HIV infected individuals (Hofbauer and Heufelder 1996). When organic etiology is 
suspected, more profound evaluations can take place, such as Doppler ultrasonography 
(arterial obstruction) or nerve conduction study (neuropathy). 
The Figure 2 summarizes the steps for the diagnosis. 
5. Treatment 
The treatment of sexual dysfunctions on HIV/AIDS patients involves pharmacotherapy, 
psychotherapy interventions, and psychoeducational approaches on safer sex.  
5.1 Pharmacotherapy  
For pharmacologycal management may be considered the changing of the antiretroviral 
used, the association of phosphodiesterase-5 inhibitors, testosterone replacement when 
hypogonadism was diagnosed, and letrozole if estradiol is increased. 
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Resolution 
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 Metabolic  
Carbohydrate 
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Fig. 2. Steps for the diagnosis 
5.1.1 Antiretrovirals 
If medication is the principal factor you can try another drug that has poor influence on 
sexual response, such as nevirapine (Collazos 2007, Collazos et al. 2002c) or atazanavir 
(Bernal et al. 2005).  
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5.1.2 Phosphodiesterase-5 inhibitors 
The use of phosphodiesterase-5 inhibitors is highly recommended in male sexual 
dysfunction, but one should be careful about drug interactions with antiretrovirals, 
particularly with protease inhibitors (especially ritonovir) because both are metabolized by 
the cytochrome P-450 system. Because the increases of serum concentration of 
phosphodiesterase-5 inhibitors when associated with protease inhibitors and cetoconazol, 
the dosage should be reduced (Merry et al. 1999, Rosen et al. 2006). The phosphodiesterase-5 
inhibitors most often used are sildenafil, tadalafil and vardenafil. 
Poppers  (amyl nitrate) are contraindicated by men user of phosphodiesterase-5 inhibitors 
because lowers blood pressure especially in combination with phosphodiesterase-5 
inhibitors.  
5.1.3 Testosterone replacement 
If the patient reaches the diagnostic criteria for hypogonadism there is some options for 
testosterone replacement.  
On the other side, testosterone replacement is not prescribed for HIV patients without 
decreases on free testosterone blood levels because does not improve sexual dysfunctions 
have been reported in this condition, and they will be exposed to the adverse effects 
(Collazos 2007). Sometimes testosterone replacement could be problematic even to 
hypogonadal male, as in the report of three HIV infected patients with erectile dysfunction 
whose present low testosterone and SHBG despite are receiving long-term oxandrolone in 
addition to testosterone replacement therapy, beyond HAART. Discontinuation of 
oxandrolone led to the normalization or improvement of testosterone levels in all three 
patients with symptomatic improvement in one patient. The authors hypothesized the first 
pass metabolism of orally administered oxandrolone may decrease hepatic synthesis of 
SHBG, allowing exogenously supplied testosterone to be excreted (Wasserman, Segal-
Maurer and Rubin 2008). 
By the way, the testosterone replacement shows good results in sexual dysfunction of most 
of hypogonadal HIV infected individuals (Cofrancesco, Whalen and Dobs 1997, Rabkin, 
Rabkin and Wagner 1997, Rabkin, Wagner and Rabkin 1999, Rabkin, Wagner and Rabkin 
2000, Seftel et al. 2004) and the replacement by testosterone gel topic shows good benefits 
(Schrader et al. 2005). 
5.1.4 Letrozole 
Finally, some improvement in sexual desire has been reported in a few patients on 
HAART who were treated with letrozole, an aromatase inhibitor that inhibits the 
conversion of testosterone to estradiol. Thirteen men who have sex with men on HAART 
with low sexual desire as well as raised estradiol levels were randomly allocated to 
receive either parenteral testosterone or letrozole for six weeks. Standardized instruments 
pointed out improvement in desire, and frequency of sexual acts in both treatment arms 
(Richardson et al. 2007). 
5.2 Psychotherapy  
The psychotherapic approaches on sexual dysfunction of HIV infected people involve 
supportive, processual, psychosexual, and psychoeducational therapies. 
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5.2.1 Supportive 
If the most important factor is the psychogenic can use supportive therapy in early period 
after HIV diagnosis. It should foccuses in demystify the stigmas from HIV/AIDS as mortal 
disease and as associated to non conventional sex behavior. The supportive approach would 
diminish the fear and guilt.  
A structured supportive approach could be necessary for the women who suffered sexual 
violence could overcoming and retake sexual life. 
5.2.2 Processual 
People who have severe sexual conflicts because grown in a family with high sexual 
repression or suffered childhood sexual abuse, a processual approach could be recomended 
as psychoanalysis. 
5.2.3 Psychosexual 
Psychosexual therapy such as sensitive focus or masturbation training are indicated when 
the acceptance of HIV seropositivity is solved and the sexual dysfunctions remains. 
5.2.4 Psychoeducational 
As most of the population did not receive sexual education, the psychoeducational 
approach is always useful involving anatomy concepts, the differences between male and 
female sexual response, e.g.  
5.3 Psychoeducational approach on safer sex 
Psychoeducational approach on safer sex is offered concomitant with the treatment of the 
sexual dysfunction. Always the approach involves the patient and his or her partner. Safer 
sex counseling is fundamental for explaining the risk for contact with different strains of 
HIV, and favouring the development of the resistence to antiretrovirals.  
Finally, psychoeducational approach should stimulate lifestyle modification including safer 
sex, exercise, recreational drugs information, modifications of cardiovascular risk factors 
(Rosen et al. 2006). 
The Figure 3 summarizes the treatment. 
6. Prognosis 
The sexual function before HIV diagnosis, the current physical and mental health, and the 
psychosocial support are important factors to improve sexual response. A medical team 
updated with knowledge on human sexuality is essential for diagnosis, and treatment of the 
sexual dysfunctions. When these conditions are preserved the results on therapeutics are 
good (Wasserman et al. 2008, Richardson et al. 2007, Schrader et al. 2005). 
The problem is that in many times the sexual issues are not investigated by health 
professionals, and just a few of patients will talk about sexual problems spontaneously. As 
sexual dysfunction is so prevalent in general population and in people living with HIV, a lot 
of them, keep without caring on sexual difficulties. On addiction, sexual dysfunction has 
impact on quality of life, very often influencing negative attitudes by the individual, 
including bad adherence to antiretroviral regimens, and to safer sex strategies (Trotta et al. 
2007, Trotta et al. 2008). Moreover, HIV infected people with sexual dysfuntion have  
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Intervention  Problem  Management strategy 
1. Pharmacotherapy  Antiretrovirals  Change medication 
 
Association with 
Phosphodiesterase-5 
inhibitors 
Reduce the dosage 
Does not use with 
poppers 
 Hypogonadism 
Testosterone 
replacement 
 
Estradiol increased (low 
sex desire) 
Letrozole  
2. Psychotherapy 
Early period after HIV 
diagnosis 
Supportive therapy 
 
Women who suffered 
sexual violence 
Supportive therapy 
 
Severe sexual repression 
Childhood sexual abuse 
Dysfunctional family 
Psychoanalysis  
 
Poor sexual education 
Poor knowledge on 
human sexuality 
Psychoeducational 
therapy 
3. Psychoeducational on safer 
sex 
Poor knowledge on 
sexual health 
Strategies for safer sex to 
the patient and to the 
partner 
Fig. 3. Interventions 
increased risk of transmission of drug-resistant strains because the higher sexual risk 
behavior, and inadvertent use of phosphodiesterase-5 inhibitors without medical 
recommendations with higher likelihood of negative interaction with antiretrovirals (Trotta 
et al. 2007, Trotta et al. 2008). 
Another important point is on the scarcity of health professional team with expertise in 
human sexuality. A so private issue needs professionals with hability to approach on these 
intimate issues of the patients. Otherwise the patients do not open your sexual problems to 
them.  
When the patient receives attention on your sexual life, he feels valuable, and will be more 
open to engage in positive ways as on adherence to medications as on safer sex strategies. 
7. Conclusion 
Sexuality is a very important point to quality of life. A person who becomes infected by HIV 
particularly by sexual contact could be extremely confused about continuing engaging in 
sexual intercourses. The consequences mostly are negative attitudes toward life, harm on 
quality of life, sexual risk behaviors, and bad adherence to antiretrovirals. People who are 
living with HIV/AIDS are extremely important to epidemia control. Take care of your 
sexual life may improve your self steam and your protective behaviors. 
By the way, the approach on sexual dysfunction in HIV infected people involves multiple 
variables and includes the assessment on clinical history (morbid conditions, medications), 
sexual history (family and own), sexual function (male and female), and laboratory studies 
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(hormonal, metabolic). The management strategies by health professionals with expertise in 
human sexuality involves pharmacology and psychotherapy interventions. Always the 
psychoeducational approach on safer sex will be developed in parallel with others 
interventions. The recovery of the sexual function, associated with a good adherence to safe 
sex practices, will improve the quality of life of the people living with HIV/AIDS and help 
controlling the epidemia. 
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